Special Issue

Lipidomics and Metabolic Biomarkers in Heart Disease

Message from the Guest Editors

Metabolic and lipidomic biomarker research is rapidly reshaping our understanding of heart disease, offering transformative opportunities for improved risk assessment, early diagnosis, and personalized patient management, Advances in lipidomics and metabolomics provide powerful tools for unraveling the complexity of cardiovascular health and disease, extending far beyond traditional metrics to illuminate a diverse range of molecular signatures and pathways involved in heart disease progression and outcomes. This Special Issue invites original research articles, comprehensive reviews, and methodological papers focused on the role of lipidomic and metabolic biomarkers in all aspects of heart disease, includingbut not limited to-coronary artery disease, heart failure, arrhythmias, acute ischemic events, and cardiometabolic risk. Of special interest are studies examining molecular and metabolic mechanisms underlying acute and chronic presentations and diagnoses, alongside innovative approaches to biomarker integration in clinical care and forensic investigations.

Guest Editors

Dr. Davide Radaelli


Department of Medicine, Surgery and Health, University of Trieste, 34149 Trieste, Italy

Dr. Matteo Scopetti

Department of Medical Surgical Sciences and Translational Medicine, "Sapienza" University of Rome, 00189 Roma, Italy

Deadline for manuscript submissions

30 June 2026



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/260439

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/ metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

